COVID-19 大流行期间原发性皮肤淋巴瘤患者的管理：欧洲癌症研究与治疗组织皮肤淋巴瘤小组指南。
Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.
机构信息
2nd Dermatology Department, National and Kapodistrian University of Athens, Athens, Greece.
University Hospital Birmingham, Birmingham, UK.
出版信息
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1633-1636. doi: 10.1111/jdv.16593. Epub 2020 Jul 7.
Abstract
COVID‐19 SPECIAL FORUM. 2020; 34: e346–e380.
摘要
新型冠状病毒肺炎专题论坛. 2020; 34: e346–e380.
相似文献
1
Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.COVID-19 大流行期间原发性皮肤淋巴瘤患者的管理：欧洲癌症研究与治疗组织皮肤淋巴瘤小组指南。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1633-1636. doi: 10.1111/jdv.16593. Epub 2020 Jul 7.
2
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic.美国皮肤淋巴瘤协会关于在2019冠状病毒病大流行期间治疗皮肤淋巴瘤的建议。
J Am Acad Dermatol. 2020 Aug;83(2):703-704. doi: 10.1016/j.jaad.2020.04.049. Epub 2020 Apr 16.
3
COVID-19 Board: Our Multidisciplinary Cutaneous Oncology Tumor Board During the Coronavirus-19 Pandemic.COVID-19 病例讨论会：新冠疫情期间我们的多学科皮肤肿瘤病例讨论会
Dermatol Surg. 2020 Sep;46(9):1224-1225. doi: 10.1097/DSS.0000000000002568.
4
Radiotherapy in the era of COVID-19.新冠疫情时代的放射治疗
Expert Rev Anticancer Ther. 2020 Aug;20(8):625-627. doi: 10.1080/14737140.2020.1785290. Epub 2020 Jul 7.
5
Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.2019冠状病毒病大流行期间自身免疫性大疱性疾病管理的专家建议。
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e302-e303. doi: 10.1111/jdv.16525. Epub 2020 Jun 4.
6
The implications of COVID-19 in radiation oncology in the United States.2019年冠状病毒病对美国放射肿瘤学的影响。
Curr Oncol. 2020 Oct;27(5):279-280. doi: 10.3747/co.27.7095. Epub 2020 Oct 1.
7
Metastatic melanoma treatment with checkpoint inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit.在 COVID-19 时代使用检查点抑制剂治疗转移性黑色素瘤：来自意大利皮肤癌科的经验。
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1395-1396. doi: 10.1111/jdv.16586. Epub 2020 Jun 4.
8
Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome.新型冠状病毒肺炎的皮肤表现：巴塞罗那和罗马的经验
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e306-e307. doi: 10.1111/jdv.16530.
9
Cutaneous manifestations of COVID-19: A preliminary review.新型冠状病毒肺炎的皮肤表现：初步综述
J Am Acad Dermatol. 2020 Aug;83(2):687-690. doi: 10.1016/j.jaad.2020.05.059. Epub 2020 May 16.
10
Cutaneous manifestation of COVID-19 reporting from Middle-Eastern countries: A point of view!中东国家关于新型冠状病毒肺炎皮肤表现的报告：一种观点！
Int J Dermatol. 2020 Dec;59(12):1547-1548. doi: 10.1111/ijd.15258. Epub 2020 Oct 24.
引用本文的文献
1
Cutaneous T-cell Lymphoma Diagnostic and Therapeutic Trends amidst the COVID-19 Pandemic.COVID-19 大流行期间皮肤 T 细胞淋巴瘤的诊断和治疗趋势。
Acta Derm Venereol. 2024 Jul 15;104:adv40505. doi: 10.2340/actadv.v104.40505.
2
Primary cutaneous lymphoma and risk for severe COVID-19: a prospective study of 48 cases in Morocco.原发性皮肤淋巴瘤与重症 COVID-19 风险：摩洛哥 48 例病例的前瞻性研究
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e512-e514. doi: 10.1111/jdv.18057. Epub 2022 Mar 17.
3
Impact of COVID-19 in patients with lymphoid malignancies.新型冠状病毒肺炎对淋巴系统恶性肿瘤患者的影响。
World J Virol. 2021 May 25;10(3):97-110. doi: 10.5501/wjv.v10.i3.97.
4
Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry.原发性皮肤淋巴瘤患者有患重症COVID-19的风险。来自西班牙原发性皮肤淋巴瘤登记处的数据。
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e624-e626. doi: 10.1111/jdv.17430. Epub 2021 Jul 2.
5
Management of primary cutaneous lymphomas during the COVID-19 pandemic.COVID-19 大流行期间原发性皮肤淋巴瘤的治疗管理。
Clin Dermatol. 2021 Jan-Feb;39(1):64-75. doi: 10.1016/j.clindermatol.2020.12.014. Epub 2021 Jan 9.
6
Impact of COVID-19 pandemic on the management of cutaneous lymphomas.2019冠状病毒病大流行对皮肤淋巴瘤管理的影响。
Clin Dermatol. 2021 Jan-Feb;39(1):169-171. doi: 10.1016/j.clindermatol.2020.09.002. Epub 2020 Sep 7.
7
Corrigendum: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.勘误：2019冠状病毒病大流行期间原发性皮肤淋巴瘤患者的管理：欧洲癌症研究与治疗组织皮肤淋巴瘤工作组指南。
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2922. doi: 10.1111/jdv.16897.
8
Cancer or COVID-19? A Review of Guidelines for Safe Cancer Care in the Wake of the Pandemic.癌症还是新冠疫情？大流行之后安全癌症护理指南综述。
SN Compr Clin Med. 2020;2(12):2691-2701. doi: 10.1007/s42399-020-00632-2. Epub 2020 Nov 21.
9
Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy.新冠疫情对意大利一个治疗性血液成分单采单位工作的影响。
Transfus Apher Sci. 2020 Dec;59(6):102925. doi: 10.1016/j.transci.2020.102925. Epub 2020 Aug 25.
10
The skin in the era of coronavirus pandemic.新冠疫情时代的皮肤问题
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1384-1385. doi: 10.1111/jdv.16718.
本文引用的文献
1
Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. 关于癌症患者中 SARS-CoV-2 的常见问题解答——为照顾恶性疾病患者的临床医生提供的建议。
Leukemia. 2020 Jun;34(6):1487-1494. doi: 10.1038/s41375-020-0832-y. Epub 2020 May 1.
2
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.在2019冠状病毒病大流行期间管理癌症护理：为实现共同目标而灵活应变与协作。
J Natl Compr Canc Netw. 2020 Mar 20:1-4. doi: 10.6004/jnccn.2020.7560.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis.新冠病毒病，一种表现为过敏性肺炎的临床综合征。
Infect Chemother. 2020 Mar;52(1):110-112. doi: 10.3947/ic.2020.52.1.110. Epub 2020 Mar 10.
5
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
6
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
7
Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents.冠状病毒在无生命表面上的持久性及其用杀生物剂灭活。
J Hosp Infect. 2020 Mar;104(3):246-251. doi: 10.1016/j.jhin.2020.01.022. Epub 2020 Feb 6.
8
Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome?蕈样肉芽肿和赛泽里综合征的生存：我们如何预测结局？
J Invest Dermatol. 2020 Feb;140(2):281-283. doi: 10.1016/j.jid.2019.08.440.
9
Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-Analysis.蕈样肉芽肿的总生存期：一项系统评价和荟萃分析。
J Invest Dermatol. 2020 Feb;140(2):495-497.e5. doi: 10.1016/j.jid.2019.07.712. Epub 2019 Aug 26.
10
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.来自前瞻性皮肤淋巴瘤国际预后指数（PROCLIPI）研究的蕈样肉芽肿/赛塞里综合征中与生活质量显著较差相关的特征。
Br J Dermatol. 2020 Mar;182(3):770-779. doi: 10.1111/bjd.18089. Epub 2019 Jul 28.
Zotero 插件